NCT06196840 - Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 24, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

October 31, 2029

Conditions

Neovascular Age-Related Macular Degeneration

Interventions

GENETIC

LX102 subretinal injection

LX102: AAV-based gene therapy comprised of codon-optimized sequence encoding VEGF-trap

BIOLOGICAL

Aflibercept intravitreal injection

Commercially available Active Comparator

Trial Locations (11)

Anhui Provincial Hospital, Hefei

Zhejiang University Eye Hospital, Hangzhou

Peking Union Medical College Hospital, Beijing

West China Hospital of Sichuan University, Chengdu

Guangzhou Aier Eye Hospital, Guangzhou

Zhongshan Ophthalmic Center of Sun Yat-Sen University, Guangzhou

Shanghai Eye and ENT Hospital, Shanghai

Shanghai General Hospital, Shanghai

Shanxi Eye Hospital, Taiyuan

Tianjin Medical University Eye Hospital, Tianjin

Xuzhou No.1 People's Hospital, Xuzhou